Inhibikase Therapeutics, Inc.’s IKT share price has dipped by 5.30%, which has investors questioning if this is right time to buy.

Inhibikase Therapeutics is meanwhile running early-stage trials of a c-Abl inhibitor and Denali Therapeutics/Biogen are working on an LRRK2 inhibitor in Parkinson's, both hoping to show that the ...

298380.KQ ABL Bio Inc.